Targeting mTOR pathways with rapamycin and its analogs, such as Apitolisib (GDC-0980) and NVP-BEZ235, can modulate GBM TME and improve T cell functionality by inhibiting mTORC1 [185,203]. Here, MTOR is linked to glioblastoma.